Nesfrotamig Biosimilar Bispecific Antibody (HER2 × 4-1BB) for Research

Cat No.: GMP-Bios-INN-1298

Anti-ERBB2/CD340/HER2 therapeutic antibody (Pre-made Nesfrotamig biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Nesfrotamig (development codes YH32367/ABL105) is a bispecific antibody targeting HER2 (ERBB2) and 4-1BB (TNFRSF9). It is developed for solid tumors. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1298-1mg 1mg
GMP-Bios-INN-1298-10mg 10mg
GMP-Bios-INN-1298-100mg 100mg
GMP-Bios-INN-1298-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Nesfrotamig biosimilar, Bispecific Mixed mAb and scFv, Anti-ERBB2/CD340/HER2;TNFRSF9/CD137/4-1BB Antibody: Anti-HER2/ERBB2/CD340/Receptor tyrosine-protein kinase erbB-2 therapeutic antibody
INN Name Nesfrotamig
Target ERBB2/CD340/HER2;TNFRSF9/CD137/4-1BB
Format Bispecific Mixed mAb and scFv
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1;na
VD LC Kappa;Lambda
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure 6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA;None
99% SI Structure 1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL;None
95-98% SI Structure 5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL;None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC